This study demonstrated the efficacy of GLP‐1 agonists in the optimization of patients with obesity, allowing two thirds of the patients to benefit from IHR, with a tendency for lower morbidity. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.